The  	The  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
immunoglobulin  	immunoglobulin  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
primary  	primary  	 JJ	B-NP
immune  	immune  	 JJ	I-NP
deficiency 	deficiency 	 NN	I-NP
:  	:  	 :	O
an  	an  	 DT	O
evidence-based  	evidence-based  	 JJ	O
practice  	practice  	 NN	B-NP
guideline  	guideline  	 VBD	I-NP
The  	The  	 DT	O
standard  	standard  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
primary  	primary  	 JJ	B-NP
antibody  	antibody  	 NN	I-NP
deficiency  	deficiency  	 NN	I-NP
is  	is  	 VBZ	O
immunoglobulin  	immunoglobulin  	 JJ	B-NP
( 	( 	 -LRB-	O
IG 	IG 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
but  	but  	 CC	O
the  	the  	 DT	O
care  	care  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
is  	is  	 VBZ	O
complex 	complex 	 JJ	O
.  	.  	 .	O
These  	These  	 DT	O
guidelines 	guidelines 	 NNS	O
,  	,  	 ,	O
initiated  	initiated  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Canadian  	Canadian  	 JJ	O
Blood  	Blood  	 NNP	O
Services  	Services  	 NNPS	O
and  	and  	 CC	O
the  	the  	 DT	O
National  	National  	 NNP	B-NP
Advisory  	Advisory  	 NNP	I-NP
Committee  	Committee  	 NNP	I-NP
on  	on  	 IN	O
Blood  	Blood  	 NNP	O
and  	and  	 CC	O
Blood  	Blood  	 NNP	O
Products 	Products 	 NNPS	O
,  	,  	 ,	O
have  	have  	 VBP	O
been  	been  	 VBN	O
developed  	developed  	 VBN	O
to  	to  	 TO	O
facilitate  	facilitate  	 VB	O
and  	and  	 CC	O
standardize  	standardize  	 VB	O
the  	the  	 DT	O
care  	care  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
by  	by  	 IN	O
the  	the  	 DT	O
various  	various  	 JJ	O
physician  	physician  	 NN	B-NP
specialties  	specialties  	 NNS	I-NP
that  	that  	 WDT	O
are  	are  	 VBP	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
their  	their  	 PRP$	O
care 	care 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
panel  	panel  	 NN	O
of  	of  	 IN	O
national  	national  	 JJ	O
expert  	expert  	 NN	B-NP
immunologists  	immunologists  	 NNS	I-NP
and  	and  	 CC	O
methodologists  	methodologists  	 VB	O
developed  	developed  	 VBN	O
salient  	salient  	 JJ	O
clinical  	clinical  	 JJ	B-NP
questions 	questions 	 NNS	I-NP
;  	;  	 :	O
and  	and  	 CC	O
a  	a  	 DT	O
systematic 	systematic 	 JJ	O
,  	,  	 ,	O
expert 	expert 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
bibliography  	bibliography  	 JJ	B-NP
literature  	literature  	 NN	I-NP
search  	search  	 NN	I-NP
up  	up  	 RP	O
to  	to  	 TO	O
July  	July  	 NNP	O
2008  	2008  	 CD	O
was  	was  	 VBD	O
conducted 	conducted 	 VBN	O
.  	.  	 .	O
One  	One  	 CD	O
thousand  	thousand  	 CD	O
eighty-seven  	eighty-seven  	 JJ	O
citations  	citations  	 NNS	O
were  	were  	 VBD	O
retrieved 	retrieved 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
102  	102  	 CD	O
reports  	reports  	 NNS	O
were  	were  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
preparation  	preparation  	 NN	B-NP
of  	of  	 IN	O
this  	this  	 DT	O
guideline 	guideline 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
recommendations  	recommendations  	 NNS	B-NP
provide  	provide  	 VBP	O
guidance  	guidance  	 NN	O
( 	( 	 -LRB-	O
1 	1 	 LS	O
)  	)  	 -RRB-	O
on  	on  	 IN	O
the  	the  	 DT	O
complexity  	complexity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
patients 	patients 	 NNS	O
;  	;  	 :	O
( 	( 	 -LRB-	O
2 	2 	 LS	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
established  	established  	 JJ	O
benefits  	benefits  	 NNS	O
of  	of  	 IN	O
IG  	IG  	 NNP	B-NP
on  	on  	 IN	O
morbidity  	morbidity  	 NN	O
and  	and  	 CC	O
mortality 	mortality 	 NN	O
;  	;  	 :	O
( 	( 	 -LRB-	O
3 	3 	 LS	O
)  	)  	 -RRB-	O
dosage 	dosage 	 NN	O
,  	,  	 ,	O
routes  	routes  	 NNS	O
of  	of  	 IN	O
administration 	administration 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
management  	management  	 NN	O
of  	of  	 IN	O
reactions 	reactions 	 NNS	O
;  	;  	 :	O
( 	( 	 -LRB-	O
4 	4 	 LS	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
various  	various  	 JJ	O
IG  	IG  	 NNP	B-NP
formulations  	formulations  	 VBD	I-NP
available 	available 	 JJ	O
;  	;  	 :	O
( 	( 	 -LRB-	O
5 	5 	 LS	O
)  	)  	 -RRB-	O
vaccination  	vaccination  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
patients 	patients 	 NNS	O
;  	;  	 :	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
6 	6 	 CD	O
)  	)  	 -RRB-	O
research  	research  	 NN	B-NP
priorities 	priorities 	 NNS	I-NP
.  	.  	 .	O
